BTAI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 3.70%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $1,380.80

BioXcel Therapeutics Insider Trading History Chart

BioXcel Therapeutics Share Price & Price History

^$2.09

▲ +0.18 (9.42%)

As of 12/4/2025 05:00 PM ET

Days: 30 | 90 | 365

BioXcel Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/16/2024	Richard I Steinhart	CFO	Sell	36	$5.76	$207.36	1,308
12/16/2024	Vimal Mehta	CEO	Sell	194	$5.76	$1,117.44	3,725
12/16/2024	Vincent O'neill	Insider	Sell	10	$5.60	$56.00	1,247
10/3/2024	Matthew T Wiley	Insider	Sell	392	$8.80	$3,449.60	1,188
10/3/2024	Richard I Steinhart	CFO	Sell	448	$8.80	$3,942.40	1,267
9/16/2024	Frank Yocca	Insider	Sell	22	$11.04	$242.88	887
9/16/2024	Richard I Steinhart	CFO	Sell	22	$11.04	$242.88	387
9/16/2024	Vimal Mehta	CEO	Sell	123	$11.04	$1,357.92	3,229
6/17/2024	Frank Yocca	Insider	Sell	23	$20.48	$471.04	842
6/17/2024	Vimal Mehta	CEO	Sell	133	$20.48	$2,723.84	2,971
6/4/2024	Vimal Mehta	CEO	Sell	7,875	$26.08	$205,380.00	488,219
4/4/2024	Richard I Steinhart	CFO	Sell	66	$42.08	$2,777.28	297
4/4/2024	Vimal Mehta	CEO	Sell	329	$41.92	$13,791.68	2,722
4/4/2024	Vincent O'neill	Insider	Sell	10	$41.92	$419.20	338
6/15/2023	Vimal Mehta	CEO	Sell	1,875	$344.64	$646,200.00	2,493
5/22/2023	Vimal Mehta	CEO	Sell	406	$412.64	$167,531.84	2,330
5/15/2023	Javier Rodriguez	Insider	Sell	111	$437.12	$48,520.32	271
5/15/2023	Richard I Steinhart	CFO	Sell	312	$434.72	$135,632.64	93
4/6/2023	Krishnan Nandabalan	Director	Sell	3,750	$277.12	$1,039,200.00
3/20/2023	Vimal Mehta	CEO	Sell	2,156	$293.12	$631,966.72	993
3/15/2023	Frank Yocca	Insider	Sell	61	$315.04	$19,217.44	593
3/15/2023	Richard I Steinhart	CFO	Sell	130	$312.00	$40,560.00	93
1/20/2023	Frank Yocca	Insider	Sell	3,125	$480.00	$1,500,000.00	524
1/5/2023	Krishnan Nandabalan	Director	Sell	1,618	$357.44	$578,337.92
12/16/2022	Vimal Mehta	CEO	Sell	1,875	$311.04	$583,200.00	622

SEC Filings (Institutional Ownership Changes) for BioXcel Therapeutics (NASDAQ:BTAI)

30.68% of BioXcel Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

BioXcel Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/17/2025	Millennium Management LLC	1,028,053	$2.63M	0.0%	N/A	6.421%
11/4/2025	Jones Financial Companies Lllp	36,000	$97K	0.0%	+38.5%	0.225%
11/3/2025	Foundations Investment Advisors LLC	29,549	$76K	0.0%	N/A	0.185%
10/23/2025	SLT Holdings LLC	29,500	$76K	0.1%	N/A	0.184%
8/14/2025	Murchinson Ltd.	80,618	$0.15M	0.1%	-40.8%	1.330%
8/14/2025	Diversify Wealth Management LLC	15,000	$27K	0.0%	N/A	0.248%
8/13/2025	Oaktree Fund Advisors LLC	42,913	$78K	0.1%	N/A	0.709%
8/13/2025	Oaktree Capital Management LP	241,188	$0.44M	0.0%	N/A	3.983%
8/12/2025	XTX Topco Ltd	23,424	$42K	0.0%	N/A	0.387%
8/8/2025	Geode Capital Management LLC	28,182	$51K	0.0%	+27.7%	0.465%
6/27/2025	Goldman Sachs Group Inc.	24,794	$50K	0.0%	N/A	0.409%
5/16/2025	Goldman Sachs Group Inc.	24,794	$50K	0.0%	N/A	0.452%
5/16/2025	Murchinson Ltd.	136,076	$0.28M	0.0%	N/A	2.480%
2/17/2025	Squarepoint Ops LLC	72,046	$27K	0.0%	+203.9%	0.145%
2/17/2025	Millennium Management LLC	104,972	$39K	0.0%	-18.5%	0.212%
2/14/2025	Northern Trust Corp	73,910	$28K	0.0%	+81.4%	0.149%
2/13/2025	Renaissance Technologies LLC	77,900	$29K	0.0%	-40.0%	0.157%
2/13/2025	Wells Fargo & Company MN	199,010	$74K	0.0%	+7.5%	0.401%
2/12/2025	Geode Capital Management LLC	311,965	$0.12M	0.0%	+4.7%	0.629%
11/15/2024	Jane Street Group LLC	49,317	$30K	0.0%	-60.6%	0.121%
11/15/2024	State Street Corp	77,149	$47K	0.0%	-38.2%	0.189%
11/13/2024	BNP Paribas Financial Markets	44,381	$27K	0.0%	-83.8%	0.109%
9/16/2024	Point72 Asia Singapore Pte. Ltd.	30,295	$39K	0.0%	N/A	0.081%
8/15/2024	Armistice Capital LLC	2,987,000	$3.82M	0.0%	+705.2%	7.959%
8/15/2024	Point72 Asia Singapore Pte. Ltd.	30,295	$39K	0.0%	N/A	0.081%
8/12/2024	XTX Topco Ltd	46,503	$60K	0.0%	+49.0%	0.124%
7/12/2024	Rosalind Advisors Inc.	39,672	$51K	0.0%	N/A	0.106%
5/20/2024	Virtu Financial LLC	13,990	$39K	0.0%	-76.5%	0.037%
5/10/2024	Vanguard Group Inc.	1,099,375	$3.10M	0.0%	+0.9%	2.968%
2/26/2024	Virtu Financial LLC	59,514	$0.18M	0.0%	N/A	0.196%
2/14/2024	Pennant Investors LP	83,900	$0.25M	0.1%	N/A	0.276%
2/13/2024	Tower Research Capital LLC TRC	13,832	$41K	0.0%	+239.2%	0.046%
2/6/2024	Apollon Wealth Management LLC	10,537	$31K	0.0%	N/A	0.035%
2/2/2024	Truist Financial Corp	10,879	$32K	0.0%	N/A	0.036%
1/23/2024	DAVENPORT & Co LLC	35,385	$0.10M	0.0%	-42.5%	0.118%
12/6/2023	Citigroup Inc.	24,336	$62K	0.0%	-59.5%	0.083%
11/15/2023	Adage Capital Partners GP L.L.C.	200,000	$0.51M	0.0%	-89.8%	0.683%
11/13/2023	FMR LLC	2,700,727	$6.83M	0.0%	-38.2%	9.227%
10/27/2023	Hennion & Walsh Asset Management Inc.	33,940	$86K	0.0%	+89.5%	0.116%
10/24/2023	Bank of New York Mellon Corp	128,022	$0.32M	0.0%	+13.2%	0.437%
10/12/2023	SeaCrest Wealth Management LLC	16,550	$42K	0.0%	-20.0%	0.057%
8/14/2023	Driehaus Capital Management LLC	22,220	$0.15M	0.0%	-94.3%	0.076%
8/11/2023	E Fund Management Co. Ltd.	10,628	$71K	0.0%	N/A	0.036%
8/10/2023	Profund Advisors LLC	35,475	$0.24M	0.0%	+29.2%	0.122%
8/10/2023	US Bancorp DE	14,072	$94K	0.0%	+42,542.4%	0.048%
8/9/2023	BNP Paribas Arbitrage SNC	69,994	$0.47M	0.0%	-38.5%	0.240%
7/25/2023	Raymond James & Associates	18,648	$0.12M	0.0%	+32.7%	0.064%
7/20/2023	DAVENPORT & Co LLC	59,705	$0.40M	0.0%	-25.6%	0.205%
7/19/2023	Artemis Investment Management LLP	895,048	$5.96M	0.1%	-8.8%	3.069%
7/14/2023	SeaCrest Wealth Management LLC	20,700	$0.14M	0.0%	+38.9%	0.071%
5/12/2023	AlphaCentric Advisors LLC	40,000	$0.75M	0.5%	-20.0%	0.138%
5/12/2023	SeaCrest Wealth Management LLC	14,907	$0.28M	0.0%	N/A	0.051%
5/12/2023	Profund Advisors LLC	27,462	$0.51M	0.0%	N/A	0.095%
5/11/2023	FMR LLC	4,276,693	$79.80M	0.0%	+1.7%	14.742%
5/11/2023	Citigroup Inc.	118,975	$2.22M	0.0%	+19,120.5%	0.410%
5/10/2023	Tocqueville Asset Management L.P.	37,000	$0.69M	0.0%	-6.1%	0.128%
5/8/2023	Federated Hermes Inc.	61,730	$1.15M	0.0%	N/A	0.213%
5/8/2023	Zurcher Kantonalbank Zurich Cantonalbank	12,103	$0.23M	0.0%	+8.2%	0.042%
5/5/2023	Truist Financial Corp	11,353	$0.21M	0.0%	-4.9%	0.039%
5/5/2023	Artemis Investment Management LLP	981,472	$18.28M	0.2%	-26.4%	3.383%
5/4/2023	Barclays PLC	56,023	$1.05M	0.0%	+990.8%	0.193%
5/4/2023	Mirae Asset Global Investments Co. Ltd.	14,137	$0.26M	0.0%	N/A	0.049%
4/27/2023	DAVENPORT & Co LLC	80,295	$1.50M	0.0%	-48.9%	0.277%
4/21/2023	Capital Investment Advisory Services LLC	17,325	$0.32M	0.0%	N/A	0.060%
4/20/2023	Hennion & Walsh Asset Management Inc.	37,887	$0.71M	0.0%	-3.3%	0.131%
4/14/2023	Raymond James & Associates	14,052	$0.26M	0.0%	-11.8%	0.048%
4/13/2023	Allspring Global Investments Holdings LLC	49,311	$0.92M	0.0%	N/A	0.170%
2/14/2023	Driehaus Capital Management LLC	505,934	$10.87M	0.2%	N/A	1.806%
2/10/2023	Sectoral Asset Management Inc.	61,156	$1.31M	0.3%	N/A	0.218%
2/9/2023	Tocqueville Asset Management L.P.	39,400	$0.85M	0.0%	+37.5%	0.141%
2/8/2023	UBS Group AG	139,214	$2.99M	0.0%	-2.9%	0.497%
2/1/2023	Zurcher Kantonalbank Zurich Cantonalbank	11,182	$0.24M	0.0%	+50.0%	0.040%
1/25/2023	Artemis Investment Management LLP	1,333,691	$28.75M	0.3%	-3.0%	4.760%
1/20/2023	DAVENPORT & Co LLC	157,105	$3.38M	0.0%	+44.7%	0.561%
1/12/2023	Hennion & Walsh Asset Management Inc.	39,185	$0.84M	0.1%	+14.5%	0.140%
11/10/2022	Connor Clark & Lunn Investment Management Ltd.	17,452	$0.21M	0.0%	N/A	0.062%
11/10/2022	UBS Group AG	143,388	$1.70M	0.0%	+22.5%	0.512%
11/9/2022	Massachusetts Financial Services Co. MA	453,877	$5.37M	0.0%	+7.3%	1.620%
11/8/2022	AlphaCentric Advisors LLC	50,000	$0.59M	0.6%	N/A	0.178%
11/7/2022	Quantbot Technologies LP	4,879	$57K	0.0%	N/A	0.017%
11/7/2022	Jump Financial LLC	26,000	$0.31M	0.0%	+22.2%	0.093%
10/26/2022	Truist Financial Corp	23,307	$0.28M	0.0%	+16.7%	0.083%
10/25/2022	Artemis Investment Management LLP	1,374,496	$16.26M	0.2%	-0.8%	4.905%
10/13/2022	PVG Asset Management Corp	15,040	$0.18M	0.7%	N/A	0.054%
10/11/2022	DAVENPORT & Co LLC	108,545	$1.28M	0.0%	+26.7%	0.387%
8/13/2022	Massachusetts Financial Services Co. MA	423,021	$5.58M	0.0%	-0.7%	1.511%
8/12/2022	Virtus ETF Advisers LLC	11,284	$0.15M	0.1%	+46.3%	0.040%
8/11/2022	Alps Advisors Inc.	16,596	$0.22M	0.0%	-42.3%	0.059%
8/8/2022	Walleye Capital LLC	36,896	$0.49M	0.0%	N/A	0.132%
8/5/2022	State Board of Administration of Florida Retirement System	17,112	$0.23M	0.0%	+45.0%	0.061%
8/4/2022	Game Plan Financial Advisors LLC	10,880	$0.14M	0.1%	N/A	0.039%
7/29/2022	SG Americas Securities LLC	43,468	$0.57M	0.0%	N/A	0.155%
7/29/2022	Crossmark Global Holdings Inc.	12,083	$0.16M	0.0%	N/A	0.043%
7/22/2022	Truist Financial Corp	19,974	$0.26M	0.0%	+3.6%	0.071%
7/22/2022	Artemis Investment Management LLP	1,384,938	$18.31M	0.2%	-3.0%	4.948%
7/18/2022	DAVENPORT & Co LLC	85,670	$1.13M	0.0%	+154.3%	0.306%
6/30/2022	Amalgamated Bank	2,816	$59K	0.0%	N/A	0.010%
5/17/2022	HITE Hedge Asset Management LLC	12,768	$0.27M	0.0%	-22.1%	0.046%
5/13/2022	Apis Capital Advisors LLC	40,000	$0.84M	1.0%	N/A	0.143%
5/11/2022	Massachusetts Financial Services Co. MA	426,177	$8.91M	0.0%	+2.8%	1.523%

Data available starting January 2016

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $2.09

$1.91

$2.11

50 Day Range

MA: $2.17

$1.61

$2.78

52 Week Range

Now: $2.09

$1.17

$9.26

Volume

461,641 shs

Average Volume

653,421 shs

Market Capitalization

$45.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Who are the company insiders with the largest holdings of BioXcel Therapeutics?: BioXcel Therapeutics' top insider investors include:
Vimal Mehta (CEO)
Richard I Steinhart (CFO)
Vincent O'neill (Insider)
Matthew T Wiley (Insider)
Frank Yocca (Insider)
Learn More about top insider investors at BioXcel Therapeutics.
Who are the major institutional investors of BioXcel Therapeutics?: BioXcel Therapeutics' top institutional shareholders include:
Millennium Management LLC — 6.42%
Jones Financial Companies Lllp — 0.22%
Foundations Investment Advisors LLC — 0.18%
SLT Holdings LLC — 0.18%
Group One Trading LLC — 0.00%
Learn More about top institutional investors of BioXcel Therapeutics stock.
Which institutional investors are selling BioXcel Therapeutics stock?: Within the last quarter, BTAI stock was sold by these institutional investors:
Group One Trading LLC
During the previous year, company insiders that have sold BioXcel Therapeutics company stock include:
Vimal Mehta (CEO)
Richard I Steinhart (CFO)
Vincent O'neill (Insider)
Learn More investors selling BioXcel Therapeutics stock.
Which institutional investors are buying BioXcel Therapeutics stock?: Within the last quarter, BTAI stock was bought by institutional investors including:
Millennium Management LLC
Foundations Investment Advisors LLC
SLT Holdings LLC
Jones Financial Companies Lllp